Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Daniel J. Weber, Executive Vice President, Chief Legal Officer, and Secretary of TTM Technologies Inc. (NASDAQ:TTMI), executed a transaction involving the sale of 8,533 shares of common stock on June 23, 2026. The total proceeds from the sale amounted to approximately $1,790,186. The shares were sold at prices ranging between $201.89 and $213.73 pe…
Robert P. Farrell, President of C&C at TTM Technologies Inc. (NASDAQ:TTMI), executed a sale of 2,920 shares on June 23, 2026. The transaction, valued at approximately $612,597, was conducted under a pre-established 10b5-1 trading plan adopted earlier in the year. The sales were specifically designated to cover tax liabilities arising from the vesti…
TTM Technologies Inc. (NASDAQ: TTMI) Senior Vice President of Information Technology Dale Martin Knecht executed a significant sale of company shares on June 23, 2026. The transaction, valued at approximately $1.4 million, was part of a pre-established trading plan designed to cover tax obligations arising from restricted stock unit vesting. This i…
Catherine A. Gridley, Executive Vice President and A&D Sector President at TTM Technologies Inc. (NASDAQ:TTMI), executed a transaction involving the sale of 8,066 shares of the company’s common stock on June 23, 2026. The total value of the sale reached approximately $1.88 million, with shares transacted at prices between $201.95 and $213.39. The t…
James P. Walsh, Chief Operating Officer at TTM Technologies Inc. (NASDAQ: TTMI), sold 2,916 shares totaling $611,766 on June 23, 2026. The transaction, executed under a pre-established 10b5-1 trading plan, was designated to cover tax obligations from restricted stock unit vesting. The sale occurs while the company navigates major growth milestones,…
Benjamin Silbermann, a director and significant shareholder of Pinterest, Inc. (NASDAQ:PINS), executed a series of stock sales totaling approximately $1.87 million on June 23 and 24, 2026. The transactions, conducted through a pre-arranged Rule 10b5-1 trading plan established in February 2026, involved the sale of 93,750 Class A Common Stock shares…
Pinterest, Inc. (NASDAQ:PINS) reported that its Chief Legal and Business Affairs Officer, Walcott Wanjiku Juanita, completed a transaction involving the sale of 14,208 shares of the company's Class A Common Stock. Executed on June 24, 2026, the sale generated approximately $279,187 in proceeds, with each share transacted at a price of $19.65. The t…
Douglas L Soder, Executive Vice President and President of the Commercial Sector at TTM Technologies Inc. (NASDAQ:TTMI), executed a sale of 8,902 shares of the company's common stock on June 23, 2026. The transaction, valued at approximately $1.87 million, was conducted under a pre-arranged 10b5-1 trading plan established on February 24, 2026. Sode…
Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc. (NASDAQ: AVTX), has sold 1,450 shares of common stock for a total value of $26,100 on June 23, 2026. The transaction was executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Prior to the sale, Doyle exercised stock options to acquire the shares at $…
Director Christopher D. Brown executed a sale of 9,900 shares in 908 Devices Inc. (NASDAQ: MASS) under a pre-arranged trading plan. The transaction took place as the company's stock approached its 52-week peak, even though recent financial results showed a significant earnings per share miss. The sale reduces Brown's direct holdings but remains par…
Kevin J. Knopp, President and CEO of 908 Devices Inc. (NASDAQ: MASS), has sold a total of 60,345 shares of the company's common stock in a series of transactions executed between June 23 and June 25, 2026. The sales, which totaled $550,624, were conducted under a pre-arranged Rule 10b5-1 trading plan established in May 2025. This executive activity…
Christopher Hite, Executive Vice President and Chairman of Partnering at Royalty Pharma plc (NASDAQ:RPRX), executed a series of share sales totaling $8,159,276 on June 23, 2026. The transactions, conducted under a pre-arranged 10b5-1 trading plan, involved the disposal of 150,000 Class A Ordinary Shares at prices between $53.39 and $54.94. This act…
Todd Dzyak, Chief Operating Officer at WidePoint Corp. (NASDAQ:WYY), executed a direct sale of 10,000 shares on June 25, 2026, realizing $240,000 at a price of $24.00 per share. This transaction reduces his direct ownership to 115,436 shares, though he retains derivative securities through stock options. The sale follows a significant 414% surge in…
Live Oak Bancshares, Inc. (NASDAQ: LOB) director William L. Williams III sold 8,400 shares of voting common stock on June 24, 2026, generating $336,453 in proceeds. The sale was executed through a Rule 10b5-1 trading plan adopted in March 2026 and shares were held in the William L. Williams Revocable Trust. Following the transaction, Williams maint…
Raymond E. Scott, President and CEO of Lear Corp (NASDAQ: LEA), executed a series of transactions on June 24, 2026, resulting in the sale of 50,000 shares of the company's common stock. The total proceeds from these sales amounted to approximately $6,768,451, with the weighted average price per share falling between $134.441 and $137.211. The trans…
Josh Folds, Chief Banking Officer at FB Bancorp, Inc. (NASDAQ:FBLA), executed a sale of 1,110 shares of the company's common stock on June 22, 2026, realizing proceeds of $16,150. The transaction occurred at a price of $14.55 per share. Following this divestment, Folds continues to hold a substantial direct stake in the company, alongside indirect …
CoreWeave CEO Michael Intrator executed a substantial divestment of 307,692 Class A Common Stock shares on June 23, 2026, totaling $32,865,847. The transactions, facilitated through a Rule 10b5-1 trading plan, were carried out at weighted average prices between $102.7157 and $111.8039 per share. This sale occurs as CoreWeave's share price has retre…
Thomas R. Cellitti, a director at Core Molding Technologies Inc. (NASDAQ:CMT), executed three separate sales of common stock between June 23 and June 25, 2026. The transactions resulted in a total value of approximately $33,970, with share prices ranging from $24.0 to $24.0662. Following these sales, Cellitti retains a direct holding of 92,393 shar…
Prospect Capital Corp (NASDAQ:PSEC) Chief Executive Officer John F. Barry has executed a significant purchase of company equity, acquiring over one million shares in late June 2026. The acquisition, valued at approximately $2.43 million, occurs against a backdrop of recent portfolio adjustments, including the announced sale of a subsidiary to MYR G…
Clean Energy Fuels Corp. (NASDAQ:CLNE) director Stephen Scully executed a recent acquisition of the company's equity, purchasing 25,000 shares on June 25, 2026. The transaction valued at $43,725 occurred while the stock was trading near its 52-week low. This insider activity follows a quarter where Clean Energy Fuels reported financial results that…
Susan M. Byrne, serving as Director Emerita at Westwood Holdings Group Inc. (NASDAQ: WHG), executed a series of stock sales totaling $79,041 over three consecutive trading days in June. These transactions were facilitated through a Rule 10b5-1 trading plan established earlier in the year. The sales occurred while WHG shares were trading close to th…
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), executed a sale of 9,500 shares of common stock valued at $5,212,519 on June 24, 2026. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025. This sale followed the acquisition of an equal number of shares through the ex…
Scott Bizily, serving as the Chief Legal Officer for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), executed a significant divestment of company equity on June 23, 2026. The transaction involved the sale of 9,810 shares of common stock, generating proceeds of $117,720 at a share price of $12.00. This disposition occurred immediately following the e…
Christy Jones, a director at Beta Bionics, Inc. (NASDAQ:BBNX), executed a sale of 1,406 shares of the company's common stock on June 24, 2026. The transaction, valued at $21,090 based on a price of $15.0 per share, was conducted under a Rule 10b5-1 trading plan adopted on February 19, 2026. Following this divestment, Jones retains direct ownership …
Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. (NASDAQ:BBNX), executed a sale of 1,258 shares of the company's common stock on June 24, 2026, totaling $18,880. The transaction was facilitated through a Rule 10b5-1 trading plan established on May 13, 2025, with shares sold at prices between $15.00 and $15.015, yielding a weighted averag…
